Multiple sclerosis disease-modifying therapy prescribing patterns in Ontario

Canadian Journal of Neurological Sciences

Volumn 40, Issue 1, 2013, Pages 67-72

  Marriott, James ^a   Mamdani, Muhammad ^b,d   Saposnik, Gustavo ^b,c,d,e   Gomes, Tara ^b,d   Manno, Michael ^a   O'connor, Paul ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Institute of Clinical and Evaluative Sciences   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ARTICLE; CANADA; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE MODIFYING THERAPY; DRUG EFFICACY; DRUG THERAPY; HUMAN; INJECTION SITE REACTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MULTIPLE SCLEROSIS; NEUROLOGIST; NORMAL HUMAN; PRESCRIPTION; PRIORITY JOURNAL;

EID: 84871289327     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S031716710001297X     Document Type: Article

References (25)

1. Jacobs LD, Cookfair DL, Rudick Ra, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. ann Neurol. 1996;39(3):285-94
2. The IFNb Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology. 1993;43(4):655-61
3. Paty DW, Li DKb. Interferon beta-1b is effective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):662-7
4. The IFNb Multiple Sclerosis Study Group and the University of british Columbia MS/MRI analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-85
5. PRISMS Study Group. Randomised double-blind placebocontrolled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-504
6. Johnson KP, brooks bR, Cohen Ja, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, doubleblind, placebo-controlled trial. Neurology. 1995(7);45:1268-76
7. Mikol DD, barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer acetate in Relapsing MS Disease [REGaRD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7 (10):903-14
8. O'Connor P, Filippi M, arnason b, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsingremitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-97
9. Gajofatto a, bacchetti P, Grimes b, et al. Switching first-line disease-modifying therapy after failure: Impact on the course of relapsing-remitting multiple sclerosis. Mult Scler. 2009;15(1): 50-8
10. Noyes K, bajorska a, Chappel a, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A populationbased study. Neurology. 2011;77(4):355-63
11. Gastwirth JL. The Estimation of the Lorenz Curve and Gini Index. Rev Econ Stat. 1972;54(3):306-16
12. Lee W-C. Characterizing exposure/disease association in human populations using the Lorenz curve and Gini index. Stat Med. 1997:16(7):729-39
13. brown MC. Using Gini-style indices to evaluate the spatial patterns of health practitioners: Theoretical considerations and an application based on alberta data. Soc Sci Med. 1994;38(9): 1243-56
14. Hallas J, Nissen a. Individualized drug utilization statistics. Eur J Clin Pharmacol. 1994;47(4):367-72
15. Ogwang T. a convenient method of computing the Gini index and its standard error. Oxford bull Econ Statist. 2000;62(1):123-9
16. Ozminkowski RJ, Marder WD, Hawkins K, et al. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. Clin Ther. 2004;26(8):1341-54
17. avasarala JR, O'Donovan Ca, Roach SE, et al. analysis of NaMCS data for multiple sclerosis, 1998-2004. bMC Med. 2007;5:6
18. Lundy J, Craig bM. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: Analysis of claims data from the medicare current beneficiary survey. Clin Ther. 2006;28 (1):140-5
19. Lo aC, Hadjimichael O, Vollmer TL. Treatment patterns of multiple sclerosis patients: A comparison of veterans and nonveterans using the NaRCOMS registry. Mult Scler. 2005;11(1):33-40
20. Shabas D, Heffner M. Multiple sclerosis management for lowincome minorities. Mult Scler. 2005;11(6):635-40
21. Iezzoni LI, Ngo LH, Kinkel RP. Working-age persons with multiple sclerosis and access to disease-modifying medications. Mult Scler. 2008;14(1):112-22
22. Minden SL, Hoaglin DC, Hadden L, et al. access to and utilization of neurologists by people with multiple sclerosis. Neurology. 2008;70(13 Pt 2):1141-9
23. Torkildsen Ø, Grytten N, Myhr KM. Immunomodulatory treatment of multiple sclerosis in Norway. acta Neurol Scand Suppl. 2007; 187:46-50
24. Tremlett HL, Luscombe DK, Wiles CM. Prescribing for multiple sclerosis patients in general practice: A case-control study. J Clin Pharm Ther. 2001;26(6):437-44
25. Sketris IS, brown M, Murray TJ, et al. Drug therapy in multiple sclerosis: A study of Nova Scotia senior citizens. Clin Ther. 1996; 18(2):303-18